Nanite, a Boston, MA-based non-viral gene delivery company, received up to $2M in funding.
The round was led by the Cystic Fibrosis Foundation.
The company intends to use the funds for the development of a gene delivery technologies for the lung. This investment builds on a $6M seed financing recently announced by the company.
Led by CEO Sean Kevlahan, Nanite is a non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. Its AI-driven platform, SAYER, combines experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.
Nanite’s proprietary platform, SAYER™, couples high-throughput synthesis with artificial intelligence (AI), and is designed to rapidly explore a large chemical space to identify the best PNP candidates for genetic material delivery to diverse tissues.
With this new funding from the Foundation, the company will work on initially developing polymer nanoparticles that can accurately deliver messenger RNA therapies to the lung while potentially better resisting the thick, sticky mucus that clogs the lungs of patients with CF. Eventually, Nanite hopes to expand these advances to deliver any type of gene therapy and target other organs affected by CF, such as the pancreas.
FinSMEs
15/03/2023